CXCL13 and myeloid sarcoma: Furthermore, a recent cross-sectional proteomic analysis revealed that the B cell chemoattractant Chemokine (C-X-C motif) ligand 13 (CXCL13), could differentiate MS patients with severe CI from those with mild CI or apparently cognitively normal profile (47).